Topic:

Sales and Marketing

Latest Headlines

Latest Headlines

Court's decision on Namenda 'hard switch' could spill over into precedent

Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version.

Point-of-care marketing shoots past DTC as pharma's latest marketing trend

Point-of-care marketing is shooting past direct-to-consumer advertising as pharma marketing's latest trend. 

Bayer runs into another German roadblock in marketing vision drug Eylea

Germany's cost-effectiveness watchdog said Bayer eye drug Eylea doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular edema.

Get-tested lung cancer campaign delivered 'surprising' number of new diagnoses

A new study shows that awareness campaigns can work--and work well. During a three-month push for lung cancer testing in the U.K., primary care doctors referred more than 3,000 extra patients to get tested. About 700 were diagnosed with lung cancer.

AbbVie's Humira competition begins with Cadila's biosimilar launch in India

Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.

Prepping for big heart drug launch, Novartis cuts 200 primary care sales staffers

Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug.

Flu-strain mutation unlocks sales opp for antiviral makers Roche, GSK

The flu season's most common viral strain has mutated, meaning this year's shots may not fully protect against it. But the so-called "drifted" strain may open up an opportunity for antiviral makers like Roche's Genentech and GlaxoSmithKline, with the CDC urging earlier use of anti-flu drugs to combat potentially severe symptoms.

Genentech's top-billing Lucentis users are also top-paid speakers: NYT

How did Genentech persuade physicians to switch from $50-a-dose Avastin to $2000-a-dose Lucentis? According to The New York Times, consultation payments may have had something to do with it.

Reckitt CEO, nearing spinoff, thinks he can outdo Big Pharma in consumer health

As shareholders gear up to vote on Reckitt Benckiser's plan to spin off its ailing pharma division, company execs are gearing up to double down on consumer health. And though a handful of pharma heavyweights are targeting the field with renewed focus, the British OTC giant believes it has the edge.

UPDATED: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit

In October, the Sanofi board fired CEO Chris Viehbacher. Now, a whistleblower lawsuit claims that part of Viehbacher's undoing was tied to a massive kickback scheme directed through consultants that was used to juice sales of diabetes meds in the States.